↑ Rising
Business
Psychedelics Stock, Up 190% This Year, Flies High Again
Definium’s LSD‑based anxiety drug sparks a 190% stock surge after a third Phase 3 triumph, reviving psychedelic biotech buzz.
Definium Therapeutics
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Definium Therapeutics
This hub groups 3 separate news trends connected to Definium Therapeutics, spanning June 22, 2026 through September 15, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 25 article observations and 22 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety
Definium Therapeutics' LSD therapy shows promise in easing anxiety in a late-stage trial.
◼ Archived
Business
🔮 fades ✓
Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge